XML 51 R25.htm IDEA: XBRL DOCUMENT v3.19.2

Statements of Operations-Additional Information (Tables)

12 Months Ended

Jun. 30, 2019

Supplemental Income Statement Elements [Abstract]

Schedule of revenues disaggregated by major product category and geographic region

Net Sales by Product Type

For the Year Ended June 30			2019						2018						2017
Animal Health
MFAs and other				$	350,468					$	336,666					$	321,430
Nutritional specialties					113,215						122,978						111,282
Vaccines					68,291						72,083						65,033
Total Animal Health				$	531,974					$	531,727					$	497,745
Mineral Nutrition					233,782						234,922						218,298
Performance Products					62,239						53,333						48,238
Total				$	827,995					$	819,982					$	764,281

Net Sales by Region

For the Year Ended June 30			2019						2018						2017
United States				$	480,101					$	490,880					$	483,794
Latin America and Canada					152,380						143,231						113,187
Europe, Middle East and Africa					105,365						110,377						95,838
Asia Pacific					90,149						75,494						71,462
Total				$	827,995					$	819,982					$	764,281

Schedule of additional information of statements of operations

For the Year Ended June 30			2019						2018						2017
Interest expense, net
Term loan				$	8,553					$	8,321					$	11,482
Revolving credit facility					3,748						2,777						2,897
Amortization of debt issuance costs and debt discount					882						883						1,015
Acquisition-related accrued interest					—						1,085						1,373
Other					494						537						105
Interest expense					13,677						13,603						16,872
Interest (income)					(1,901)						(1,693)						(1,966)
				$	11,776					$	11,910					$	14,906

For the Year Ended June 30			2019						2018						2017
Depreciation and amortization
Depreciation of property, plant and equipment				$	21,423					$	21,044					$	19,916
Amortization of intangible assets					6,092						5,851						5,950
Amortization of other assets					49						48						135
				$	27,564					$	26,943					$	26,001

For the Year Ended June 30			2019						2018						2017
Research and development expenditures				$	12,083					$	9,998					$	9,442

X

- Definition

Tabular disclosure of additional Information of statements of operations.

+ References

No definition available.

+ Details

Name:	pahc_ScheduleOfAdditionalInformationOfStatementsOfOperationsTableTextBlock
Namespace Prefix:	pahc_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SupplementalIncomeStatementElementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration